1.
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
[PubMed]
2.
Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF: Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014;123:3574-3577.
[PubMed]
3.
Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A: Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 2015;94:233-238.
[PubMed]
4.
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-2667.
[PubMed]
5.
Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U: PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. Nat Cell Biol 2001;3:512-516.
[PubMed]
6.
Jones AV, Cross NC: Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004;61:2912-2923.
[PubMed]
7.
Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-316.
[PubMed]
8.
Reiter A, Gotlib J: Myeloid neoplasms with eosinophilia. Blood 2017;129:704-714.
[PubMed]
9.
Hori A, Toda T: Regulation of centriolar satellite integrity and its physiology. Cell Mol Life Sci 2017;74:213-29.
[PubMed]
10.
Delaval B, Lelièvre H, Birnbaum D: Myeloproliferative disorders: the centrosome connection. Leukemia 2005;19:1739-1744.
[PubMed]
11.
Mahon FX: Discontinuation of TKI therapy and “functional” cure for CML. Best Pract Res Clin Haematol 2016;29:308-313.
[PubMed]
12.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405.
[PubMed]
You do not currently have access to this content.